\-\ Texto\\:\\ \ \(0\)\
\-\ pe\\ \\-\\ vitals\\:\\ stable\\.\ \(0\)\
\-\ gen\\:\\ well\\ developed\\ \\-\\ non\\ toxic\\ appearing\\ female\\ who\\ appears\\ older\\ than\\ her\\ stated\\ age\\.\ \(0\)\
\-\ neuro\\:\\ non\\ focal\\ with\\ a\\ mild\\ resting\\ tremor\\.\ \(0\)\
\-\ labs\\:\\ ca\\+\\+\\ and\\ p\\ reported\\ normal\\ over\\ the\\ past\\ three\\ years\ \(0\)\
\-\ treatment\\:\ \(3\)\
\-\ may\\ include\\ chelators\\.\ \(0\)\
\-\ antioxidants\\.\ \(0\)\
\-\ calcium\\ antagonists\\.\ \(0\)\
\-\ non\\ contrast\\ enhanced\\ ct\\ of\\ the\\ head\\.\ \(0\)\
\-\ \\ \\-\\ bilateral\\ basal\\ ganglia\\ and\\ cerebellar\\ calcifications\\.\ \(0\)\
\-\ \\ \\-\\ no\\ acute\\ intra\\-axial\\ pathology\\ is\\ noted\\.\ \(0\)\
\-\ fahr\\'s\\ disease\\.\ \(0\)\
\-\ fahr\\'s\\ disease\\.\ \(0\)\
\-\ normal\\ symmetric\\ basal\\ ganglia\\ calcifications\\ in\\ the\\ elderly\\.\ \(0\)\
\-\ pathologic\\ basal\\ ganglia\\ calcifications\\ from\\ endocrine\\ or\\ neuropsychiatric\\ causes\\.\ \(0\)\
\-\ 50\\ year\\ old\\ woman\\ who\\ presents\\ with\\ subacute\\ mental\\ status\\ changes\\.\ \(1\)\
\-\ fahr\\'s\\ disease\\ is\\ a\\ rare\\ degenerative\\ neurological\\ disorder\\ characterized\\ by\\ extensive\\ bilateral\\ basal\\ ganglia\\ calcifications\\ that\\ can\\ lead\\ to\\ movement\\ disorders\\ and\\ neuropsychiatric\\ manifestations\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ ganglia\\:\\ 0\\.12063081841313604\ \(0\)\
\-\ basal\\:\\ 0\\.10746310339692064\ \(0\)\
\-\ neuropsychiatric\\:\\ 0\\.10247205603926356\ \(0\)\
\-\ fahr\\:\\ 0\\.099394213952171\ \(0\)\
\-\ calcifications\\:\\ 0\\.0876458966795242\ \(0\)\
\-\ non\\:\\ 0\\.0730823730047278\ \(0\)\
\-\ chelators\\:\\ 0\\.06079667878597585\ \(0\)\
\-\ \\-antioxidants\\:\\ 0\\.06079667878597585\ \(0\)\
\-\ \\-calcium\\:\\ 0\\.06079667878597585\ \(0\)\
\-\ \\-fahr\\:\\ 0\\.06079667878597585\ \(0\)\
\-\ \\-may\\:\\ 0\\.05601635340280381\ \(0\)\
\-\ antagonists\\:\\ 0\\.05601635340280381\ \(0\)\
\-\ \\-pathologic\\:\\ 0\\.05601635340280381\ \(0\)\
\-\ \\-\\:\\ 0\\.05053044024023072\ \(0\)\
\-\ \\-normal\\:\\ 0\\.04843971692923064\ \(0\)\
\-\ ca\\+\\+\\:\\ 0\\.04737660879249093\ \(0\)\
\-\ intra\\-axial\\:\\ 0\\.04212047050251233\ \(0\)\
\-\ tremor\\:\\ 0\\.04125727641317436\ \(0\)\
\-\ resting\\:\\ 0\\.040490203067586605\ \(0\)\
\-\ \\'s\\:\\ 0\\.03898027486276645\ \(0\)\
\-\ \\:\\:\\ 0\\.03897499365485052\ \(0\)\
\-\ endocrine\\:\\ 0\\.03647695103000232\ \(0\)\
\-\ elderly\\:\\ 0\\.034698819241711976\ \(0\)\
\-\ toxic\\:\\ 0\\.034543834028939166\ \(0\)\
\-\ manifestations\\:\\ 0\\.03354672210610393\ \(0\)\
\-\ gen\\:\\ 0\\.03244582455029784\ \(0\)\
\-\ stated\\:\\ 0\\.03211472648694363\ \(0\)\
\-\ who\\:\\ 0\\.030730598746782096\ \(0\)\
\-\ neuro\\:\\ 0\\.030405511563463758\ \(0\)\
\-\ p\\:\\ 0\\.030239321552573684\ \(0\)\
\-\ subacute\\:\\ 0\\.030239321552573684\ \(0\)\
\-\ older\\:\\ 0\\.029687302878963092\ \(0\)\
\-\ movement\\:\\ 0\\.02946361132204479\ \(0\)\
\-\ characterized\\:\\ 0\\.029318415396542497\ \(0\)\
\-\ disease\\:\\ 0\\.028898018094118016\ \(0\)\
\-\ bilateral\\:\\ 0\\.028604382473302676\ \(0\)\
\-\ lead\\:\\ 0\\.02825530725980278\ \(0\)\
\-\ vitals\\:\\ 0\\.028194004174166603\ \(0\)\
\-\ disorders\\:\\ 0\\.028194004174166603\ \(0\)\
\-\ mental\\:\\ 0\\.02749796335630481\ \(0\)\
\-\ symmetric\\:\\ 0\\.026916300263658252\ \(0\)\
\-\ degenerative\\:\\ 0\\.02671638621625651\ \(0\)\
\-\ pe\\:\\ 0\\.02647437711410982\ \(0\)\
\-\ disorder\\:\\ 0\\.02647437711410982\ \(0\)\
\-\ appearing\\:\\ 0\\.026194748876907405\ \(0\)\
\-\ neurological\\:\\ 0\\.025500169734825814\ \(0\)\
\-\ cerebellar\\:\\ 0\\.025418066958920172\ \(0\)\
\-\ enhanced\\:\\ 0\\.02521698706725496\ \(0\)\
\-\ stable\\:\\ 0\\.024291128270634524\ \(0\)\
\-\ pathology\\:\\ 0\\.024119989173257115\ \(0\)\
\-\ extensive\\:\\ 0\\.02356797049964652\ \(0\)\
\-\ causes\\:\\ 0\\.022941935846964218\ \(0\)\
\-\ rare\\:\\ 0\\.022885173783953765\ \(0\)\
\-\ developed\\:\\ 0\\.02269010679196355\ \(0\)\
\-\ 50\\:\\ 0\\.022420675976853825\ \(0\)\
\-\ appears\\:\\ 0\\.021936060833084473\ \(0\)\
\-\ reported\\:\\ 0\\.021483274831557323\ \(0\)\
\-\ status\\:\\ 0\\.021036740146080368\ \(0\)\
\-\ labs\\:\\ 0\\.020496372461621643\ \(0\)\
\-\ three\\:\\ 0\\.019866373988599383\ \(0\)\
\-\ past\\:\\ 0\\.01872551359963058\ \(0\)\
\-\ age\\:\\ 0\\.017937312589960733\ \(0\)\
\-\ her\\:\\ 0\\.01772008040334438\ \(0\)\
\-\ years\\:\\ 0\\.017305125082886084\ \(0\)\
\-\ changes\\:\\ 0\\.01688998604300042\ \(0\)\
\-\ focal\\:\\ 0\\.016830990373368288\ \(0\)\
\-\ head\\:\\ 0\\.016714491797061352\ \(0\)\
\-\ include\\:\\ 0\\.016532093020898527\ \(0\)\
\-\ mild\\:\\ 0\\.015518989337456117\ \(0\)\
\-\ than\\:\\ 0\\.015441716240815681\ \(0\)\
\-\ over\\:\\ 0\\.015004431656137672\ \(0\)\
\-\ acute\\:\\ 0\\.01455089192487238\ \(0\)\
\-\ noted\\:\\ 0\\.013968421989328232\ \(0\)\
\-\ woman\\:\\ 0\\.01361312377578556\ \(0\)\
\-\ can\\:\\ 0\\.013367050706683238\ \(0\)\
\-\ well\\:\\ 0\\.013331592779094145\ \(0\)\
\-\ contrast\\:\\ 0\\.013191556460744174\ \(0\)\
\-\ female\\:\\ 0\\.012115588078950577\ \(0\)\
\-\ presents\\:\\ 0\\.01203892617591673\ \(0\)\
\-\ treatment\\:\\ 0\\.011928392824833703\ \(0\)\
\-\ that\\:\\ 0\\.010179177438336712\ \(0\)\
\-\ by\\:\\ 0\\.009812902780999135\ \(0\)\
\-\ normal\\:\\ 0\\.009238706583442077\ \(0\)\
\-\ from\\:\\ 0\\.008734039401063534\ \(0\)\
\-\ ct\\:\\ 0\\.008243473471669262\ \(0\)\
\-\ is\\:\\ 0\\.007755734874272078\ \(0\)\
\-\ or\\:\\ 0\\.006907053441129018\ \(0\)\
\-\ year\\:\\ 0\\.006593829443261481\ \(0\)\
\-\ old\\:\\ 0\\.006034031702498307\ \(0\)\
\-\ no\\:\\ 0\\.005934097591060703\ \(0\)\
\-\ a\\:\\ 0\\.005470342094049673\ \(0\)\
\-\ and\\:\\ 0\\.0037243242565286575\ \(0\)\
\-\ \\.\\:\\ 0\\.0036723658031737527\ \(0\)\
\-\ to\\:\\ 0\\.0029452972996068015\ \(0\)\
\-\ in\\:\\ 0\\.0029061877940707234\ \(0\)\
\-\ the\\:\\ 0\\.0028603300283508784\ \(0\)\
\-\ with\\:\\ 0\\.0016138507046881342\ \(0\)\
\-\ of\\:\\ 0\\.0008034744882619892\ \(0\)\
